20/07/2025
https://www.facebook.com/share/p/15ksAUSuS6/
🧠A Single Dose Shrinks Aggressive Brain Tumors in Days
In a groundbreaking clinical trial at Mass General Cancer Center, researchers have reported a dramatic breakthrough in treating glioblastoma, one of the deadliest forms of brain cancer.
Three patients with highly aggressive glioblastoma received a single dose of a next-generation CAR-T cell therapy — and the results were astonishing.
One patient’s tumor nearly vanished.
Another saw a 60%+ reduction that lasted for over six months.
The response was seen within days of treatment.
This experimental therapy is a modified version of CAR-T (Chimeric Antigen Receptor T-cell) therapy, where a patient’s own immune cells are reprogrammed to seek out and destroy cancer cells more effectively.
What makes this trial unique is its dual-targeting approach, allowing immune cells to identify and attack multiple types of cancer cells within the tumor — a key advancement since glioblastomas are often resistant to standard treatments.
Although the tumors eventually returned, the speed and scale of the initial response have sparked hope for more effective and longer-lasting treatments for brain cancer and other hard-to-treat tumors.
🧬 This trial could mark a turning point in the fight against glioblastoma.
Source:
Massachusetts General Hospital.
"Preliminary Clinical Trial Results Show ‘Dramatic and Rapid’ Regression of Glioblastoma after Next Generation CAR-T Therapy"
https://www.massgeneral.org
